Comparative Pharmacology
Head-to-head clinical analysis: XALATAN versus YUVIWEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XALATAN versus YUVIWEL.
XALATAN vs YUVIWEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
YUVIWEL (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby decreasing their release into the synaptic cleft, which reduces dopaminergic transmission implicated in hyperkinetic movement disorders.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
No established standard dosing for YUVIWEL; drug not recognized.
None Documented
None Documented
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Terminal elimination half-life is 12 hours; steady-state reached within 48-60 hours, requiring dose adjustment in renal impairment.
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination constitutes 30%.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog